Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 7—July 2017
CME ACTIVITY - Research

Clonal Clusters and Virulence Factors of Group C and G Streptococcus Causing Severe Infections, Manitoba, Canada, 2012–2014

Sylvain A. LotherComments to Author , Walter Demczuk, Irene Martin, Michael R. Mulvey, Brenden Dufault, Philippe Lagacé-Wiens, and Yoav Keynan
Author affiliations: AuUniversity of Manitoba, Winnipeg, Manitoba, Canada (S. Lother, B. Dufault, P. Lagacé-Wiens, Y. Keynan); National Microbiology Laboratory, Winnipeg (W. Demczuk, I. Martin, M. Mulvey); Diagnostic Service Manitoba, Winnipeg (P. Lagacé-Wiens)

Cite This Article

Introduction

CME Logo

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate.

Release date: June 15, 2017; Expiration date: June 15, 2018

Learning Objectives

Upon completion of this activity, participants will be able to:

•     Identify clinical features of patients with group C and G Streptococcus (GCGS) bacteremia, based on a retrospective study in Manitoba, Canada.

•     Assess outcomes in patients with GCGS bacteremia.

•     Determine genetic determinants of GCGS bacteremia.

CME Editor

Claudia Chesley, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Claudia Chesley has disclosed no relevant financial relationships.

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed the following relevant financial relationships: owns stock, stock options, or bonds from Alnylam; Biogen; Pfizer.

Authors

Disclosures: Sylvain A. Lother, MD; Walter Demczuk, BSc; Irene Martin, BSc; Michael Mulvey, PhD; Brenden Dufault, MSc (Biostatistics); and Yoav Keynan, MD, PhD, have disclosed no relevant financial relationships. Philippe Lagacé-Wiens, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Merck, Cubist; served as a speaker or a member of a speakers bureau for Merck.

Top

Abstract

The incidence of group C and G Streptococcus (GCGS) bacteremia, which is associated with severe disease and death, is increasing. We characterized clinical features, outcomes, and genetic determinants of GCGS bacteremia for 89 patients in Winnipeg, Manitoba, Canada, who had GCGS bacteremia during 2012–2014. Of the 89 patients, 51% had bacteremia from skin and soft tissue, 70% had severe disease features, and 20% died. Whole-genome sequencing analysis was performed on isolates derived from 89 blood samples and 33 respiratory sample controls: 5 closely related genetic lineages were identified as being more likely to cause invasive disease than non-clade isolates (83% vs. 57%, p = 0.002). Virulence factors cbp, fbp, speG, sicG, gfbA, and bca clustered clonally into these clades. A clonal distribution of virulence factors may account for severe and fatal cases of bacteremia caused by invasive GCGS.

Group C and G Streptococcus (GCGS) are quickly becoming a major public health concern as the incidence of invasive infection and severe disease is increasing (16). In Manitoba, Canada, the incidence of GCGS bacteremia continues to increase, whereas the incidence of other invasive β-hemolytic streptococcal infections remains constant (1), similar to trends observed in Finland, Denmark, and Israel (35,7). These invasive infections cause severe illness, and up to 25% of patients die (2,3,79), yet the factors contributing to disease severity and death remain unclear.

Streptococcus dysgalactiae subsp. equisimilis (SDSE) is responsible for most cases of GCGS infections in humans (10,11). Historically considered nonpathogenic commensal flora, SDSE is now implicated in skin and soft tissue infections, pharyngitis, bacteremia, endocarditis, sepsis, toxic shock, and other invasive infections (3,5,9,1214) that extensively overlap with the clinical presentations of S. pyogenes (group A Streptococcus [GAS]) infections. Similar to S. pyogenes, SDSE form large β-hemolytic colonies on sheep blood agar with hyaluronic acid capsules but express Lancefield group C or G carbohydrate (15) and possess M protein, which is vital in inhibiting complement pathway activation and resisting phagocytic killing (16). SDSE is genetically closely related to S. pyogenes, sharing 61%–72% sequence homology (11,17). These pathogens can exchange genes through bacterial phages and other mechanisms (11).

Approximately 71 virulence factor genes from S. pyogenes have been identified in SDSE, including hemolysin, streptolysin, exotoxin, proteinase, adhesin, streptokinase, and hyaluronic acid genes (11,18). S. pyogenes and SDSE carry streptolysin O (slo), which is required for invasive human infection (11,19), and streptolysin S (sagA), which has been linked to necrotizing soft tissue infections (20). Furthermore, the superantigen alleles speA, C, G, H, I, K, L, M, N, O, and P, which have been identified in S. pyogenes, have infrequently been identified in SDSE, but speJ and ssa are unique to GAS, and szeN, szeP, and szeF are unique to GCGS (21). The only commonly reported superantigen of SDSE is speG (11,22,23). Other commonly found virulence factors in SDSE are lmb, gapC, sagA, hylB, slo, scpA, and ska, whereas the presence of cbp, fbp, and sicG is variable and found only in a minority of strains (22). A conclusive association between virulence profile and disease propensity or site of isolation has not been demonstrated (18,22,24).

The monitoring of emerging pathogens requires phenotypic and molecular-based typing methodologies. Multilocus sequence typing (MLST) can be useful in tracking short-chain transmission of infections, but application of whole-genome sequencing for comparative studies provides higher resolution through a genomic epidemiology approach to investigate strain relatedness and dynamics. To uncover factors that may contribute to increased GCGS pathogenesis, we describe the clinical features of 89 GCGS bloodstream infections and the distribution of sequence types (STs) and virulence factors by whole-genome sequencing of 122 invasive and noninvasive isolates. We conducted this study in accordance with the ethical principles at the University of Manitoba after obtaining approval from the Health Research Ethics Board and Research Impact Committee.

Materials and Methods

Using the records of 2 large laboratories, we retrospectively identified GCGS bacteremia cases that occurred during January 2012–December 2014 in Winnipeg, Manitoba, Canada. We identified 89 bacteremic events (defined as >1 blood culture positive for GCGS during a single hospital admission) among a total of 84 patients. We reviewed charts to obtain patient characteristics and clinical parameters for each bacteremic event. During September–December 2014, within the same geographic location as the study cohort, community physicians collected control pharyngeal swab samples from outpatients with signs or symptoms of pharyngitis. The samples, which were obtained at the physicians’ discretion, were cultured for identification of pyogenic streptococci: 33 noninvasive GCGS isolates were detected. These GCGS isolates were recovered from patients with symptomatic pharyngitis, but their symptoms were not severe and not necessarily attributable to GCGS. Although these control isolates were not from asymptomatic volunteers, the clinical differences between invasive blood stream isolates and noninvasive respiratory isolates was sufficient to compare genetic differences.

Disease Severity

We considered patients with >1 of the following to have severe GCGS disease: in-hospital death, admission to intensive care unit, need for vasopressor or ventilatory support, diagnosis of streptococcal toxic shock syndrome (STSS) or infectious endocarditis, or a high-risk Simple Clinical Score >8 or Rapid Emergency Medicine Score >10. We defined STSS according to guidelines of the Working Group on Severe Streptococcal Infections (25). We calculated Simple Clinical Scores and Rapid Emergency Medicine Scores primarily by using patient vital signs and other clinical features; high-risk scores are associated with a 9.0%–10.3% risk for death by 30 days after admission (2628).

Collection and Identification of Bacteria

At the discretion of the healthcare provider, patient blood samples were collected at symptom onset into BacT/Alert bottles (bioMérieux, Saint-Laurent, QC, Canada) according to institutional protocol and incubated using the BacT/Alert blood culture instrument (bioMérieux). Isolates were stored in frozen stocks in skim milk at −70°C and later retrieved by subculture for further analysis.

A total of 92 GCGS isolates were recorded during the study period; 90 were retrieved, 2 were lost in storage, and 1 was identified as S. equi subsp. zooepidemicus by 16S rRNA sequence similarity and excluded from the study. We plated the 89 remaining isolates onto sheep blood agar (Oxoid, Nepean, ON, Canada) and aerobically incubated them for 24 h at 37°C in the presence of 5% CO2. We confirmed isolate identification by using MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight) mass spectrometry with the MALDI BioTyper system (Bruker, Boston, MA, USA) according to the manufacturer’s protocol. To confirm isolates with ambiguous MALDI-TOF mass spectrometry identifications, we used latex agglutination to Lancefield antigens C and G and the Vitek2 system (bioMérieux) for biochemical identification. All isolates were identified as S. dysgalactiae.

Whole-Genome Sequencing

We extracted DNA from cultures, created multiplexed libraries, assembled reads, and performed core nucleotide variation phylogenetic analyses (Technical Appendix 1). In brief, we generated paired-end, 300-bp indexed reads on the Illumina MiSeq platform (Illumina, San Diego, CA, USA); the average yield was 1,015,107 reads/genome, and the average genomic coverage was 145×. Read quality was assessed by using FastQC version 0.11.4 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), assembled with SPAdes version 3.6.2 (http://cab.spbu.ru/software/spades/), and annotated with Prokka version 1.11 (http://www.vicbioinformatics.com/software.prokka.shtml), yielding an average contig length of 39,313 bp and an average N50 contig length of 82,867 bp (2931). The high-quality reads were then mapped to the publically available reference genome, S. dysgalactiae subsp. equisimilis AC-2713 (GenBank accession no. NC_019042.1), by using SMALT version 0.7.5 (http://www.sanger.ac.uk/science/tools/smalt-0). Single-nucleotide variations (SNVs) were called using FreeBayes version 0.9.20 (https://github.com/ekg/freebayes) and SAMtools mpileup (http://www.htslib.org/) (32). The percentage of bases in the core was 82.8%, and 21,746 sites were used to generate the phylogeny.

We constructed a maximum-likelihood phylogenetic tree of informative SNV positions by using PhyML version 3.0 (http://www.atgc-montpellier.fr/phyml/) (33) and visualized the tree by using FigTree version 1.4.1 (http://tree.bio.ed.ac.uk/software/figtree/) (34). We determined phylogenetic clades by cluster analysis on the full dataset of blood and respiratory isolates (n = 122) and on isolates from blood only (n = 89) by using ClusterPicker version 1.2.4 (http://hiv.bio.ed.ac.uk/software.html) with the following settings: initial and main support thresholds = 0.9, genetic distance threshold = 4.5, and the large cluster threshold = 10 (34). We submitted whole-genome sequencing read data to the NCBI Sequence Read Archive (https://www.ncbi.nlm.nih.gov/sra/) under BioProject accession number PRJNA325743.

Molecular Typing

We used the whole-genome sequencing data for in silico determination of MLST STs; virulence factors (lmb, gapC, cba, cbp, fbp, sagA, slo, hylB, spegg, sicG, fbsA, pavA, fnbA, fnbB, gfbA, scpA, scpB, bca, cylE, ska, skc and skg) (22,35); and superantigens (speA, speB, speC, speF, spegg, speH, speI, speJ, speL, mf-2, mf-3, and smeZ) (21,23). We determined Lancefield serogroups from sequences annotated with Prokka and confirmed them by serologic testing using commercial latex antisera (SSI Diagnostica, Hillerød, Denmark). We submitted MLST allelic profiles to the Streptococcus dysgalactiae MLST database (https://pubmlst.org/sdysgalactiae/). We used allelic profiles to compute a goeBURST (global optimal eBurst; http://www.phyloviz.net/goeburst/) full minimum spanning tree using PHYLOViZ (http://www.phyloviz.net/) (36); groups were assigned by a single-locus variation from a founding ST. All strains were confirmed to belong to S. dysgalactiae subsp. equisimilis by BLASTn (37) alignment of 16S rRNA sequences to reference genomes of S. dysgalactiae subsp. dysgalactiae ATCC27957 and S. dysgalactiae subsp. equisimilis ATCC12394 (PubMed accession nos. NZ_CM001076.1 and NC_017567.1, respectively).

Statistical Methods

We used descriptive statistics, χ2 test, Kruskal-Wallis test, and Fisher exact test to compare demographics between clusters of SDSE to determine whether they differed with respect to key risk factors. We used Fisher exact test to compare risk of death and other disease severity markers between ST clusters and clades. No observations were censored, so survival analysis techniques were not necessary.

Results

Patient Characteristics and Disease Severity

We investigated 89 GCGS bacteremic events in 84 patients in Winnipeg during 2012–2014. Most patients (63%) were male, and the mean age was 61 years (SD ± 18.4 years). Many patients had co-existing conditions, predominantly cardiovascular disease (47%) and diabetes mellitus (43%). The most common source of bacteremia was from skin and soft tissue infections (51%), and 37% of patients had primary bacteremia. Infectious endocarditis was confirmed or suspected in 7% of patients. No patients had necrotizing fasciitis or pharyngitis (Table 1).

In 70% of the cases, bacteremia was associated with markers of severe disease, including admission to an intensive care unit (26%) and the need for vasopressor (19%) or ventilatory (17%) support. Seventeen percent of patients had a diagnosis of STSS, and 35%–61% of patients had high-risk disease severity scores. Twenty percent of patients with GCGS bacteremia died while in the hospital (Table 2).

SDSE Isolate Characteristics

SDSE isolates from blood represented 89 (73%) of 122 total isolates; 33 (37%) of the 89 isolates were from female patients and 56 (63%) were from male patients. These isolates were classified as Lancefield groups G (63%) and C (37%). Respiratory isolates represented 27% (33/122) of the isolates; information regarding the number from female and male patients was not available. These isolates also were classified as Lancefield groups G (52%) and C (48%).

Core Single-Nucleotide Variation Phylogenetic Analysis

Phylogenetic analysis of all 122 isolates showed no association between infection type and patient sex, age, or disease severity (Technical Appendix 1 Figure). Compared with the heterogeneous nonclade isolates, those that clustered into clades A–E represented a higher proportion of blood isolates (25/45 [57%] vs. 64/77 [83%], respectively; p = 0.002). In addition, compared with the other clades combined, clade A was represented by significantly fewer blood isolates (36/38 [95%] vs. 28/39 [72%], respectively; p = 0.017). In silico molecular determinants (MLST, Lancefield serogroups, and virulence factors) were clustered in a clonal distribution (Technical Appendix 1 Figure). However, we found no significant associations when comparing blood and respiratory isolates.

Figure 1

Thumbnail of Maximum-likelihood whole-genome, core single-nucleotide variation (SNV) phylogenetic tree of 89 Streptococcus dysgalactiae subsp. equisimilis isolates from the blood of patients with group C and G Streptococcus causing severe infections, Winnipeg, Manitoba, Canada, 2012–2014. Multilocus sequence typing clonal complex relatedness groups were determined by using goeBURST (global optimal eBurst; http://www.phyloviz.net). In the mortality column, red and white squares indicate patient d

Figure 1. Maximum-likelihood whole-genome, core single-nucleotide variation (SNV) phylogenetic tree of 89 Streptococcus dysgalactiae subsp. equisimilis isolates from the blood of patients with group C and G Streptococcus causing severe infections, Winnipeg,...

Cluster analysis of the 89 blood isolates yielded 5 clades, A–E (n = 64); the other 25 heterogeneous isolates were outside these lineages. Clade A isolates were Lancefield serogroup C, clades B–E were serogroup G, and the heterogeneous nonclade isolates were serogroups C (n = 5) and G (n = 20) (Figure 1). Isolate numbers 35, 49, 26, 40, 47, 45, and 51 were most genetically distant from the other blood isolates, averaging 3,897–3,987 SNVs. The greatest difference was 5,110 SNVs between isolate numbers 30 and 51 (Technical Appendix 2). Clade C was the most genetically homogenous, showing a maximum of 138 SNVs between isolates in the clade. Clade B was the most diverse, showing a maximum difference of 600 SNVs between isolates (online Technical Appendix Table 1).

MLST

Figure 2

Thumbnail of Minimum spanning tree representing the genetic relatedness of multilocus sequence types (MLSTs) of Streptococcus dysgalactiae subsp. equisimilis isolates from patients with group C and G Streptococcus causing severe infections, Winnipeg, Manitoba, Canada, 2012–2014. Genetic relatedness was determined by full goeBURST (global optimal eBurst; http://www.phyloviz.net) analysis using Streptococcus dysgalactiae MLST allelic profiles of 7 housekeeping genes. Numbers on nodes correspond to

Figure 2. Minimum spanning tree representing the genetic relatedness of multilocus sequence types (MLSTs) of Streptococcus dysgalactiae subsp. equisimilis isolates from patients with group C and G Streptococcus causing severe infections, Winnipeg,...

STs for all 122 isolates generally correlated with specific phylogenetic clades and subclades (Figure 1; Technical Appendix 1 Figure). The most common STs were ST20 (n = 28), followed by ST17 (n = 16) and ST15 (n = 9) (Figure 2). Clade A (n = 28) consisted entirely of ST20 isolates belonging to a singleton MLST relatedness group. Clade B (n = 13) belonged to MLST clonal complex (CC) 2, in which ST15 (n = 9), ST69 (n = 1), and ST274 (n = 2) isolates grouped into subclades. An isolate with ST276 (a double-locus variant of ST15) also clustered into clade B. Clades C (n = 14) and D (n = 5) belonged to MLST CC1; clade C consisted of ST17 isolates, and clade D consisted of ST282 isolates. Clade E (n = 4) belonged to MLST CC3, in which ST63 (n = 2), ST52 (n = 1), and ST164 (n = 1) isolates grouped into subclades. Although SNV phylogenetic analysis showed that ST17 (clade C) and ST15 (clade B) isolates were closely related, large variations in MLST separated them into distinct clonal clusters (Figure 2).

Figure 3

Thumbnail of Prevalence of sequence types, as characterized by multilocus sequence typing, among blood and respiratory isolates of Streptococcus dysgalactiae subsp. equisimilis from patients with group C and G Streptococcus causing severe infections, Winnipeg, Manitoba, Canada, 2012–2014.

Figure 3. Prevalence of sequence types, as characterized by multilocus sequence typing, among blood and respiratory isolates of Streptococcus dysgalactiae subsp. equisimilis from patients with group C and G Streptococcus causing severe...

A total of 18 STs were unique to blood isolates: STs 4, 8, 38, 44, 52, 59, 63, 84, 138, 154, 265, 269, 270, 274, 275, 276, 279, and 282. A total of 8 STs were unique to respiratory isolates: STs 49, 68, 206, 266, 273, 277, 280, and 283 (Figure 3).

Invasive Polymicrobial Infections

Polymicrobial bacteremia with organisms other than GCGS alone was present in 18% (16/89) of patients. In 4 patients with non-GCGS organisms plus GCGS isolates (i.e., isolate nos. 3 and 57, which clustered in clade B; and nonclade nos. 12 and 74), the non-GCGS organisms were believed to represent 1) contaminants at the time of sample collection or 2) the nonprimary pathogen. Staphylococcus aureus co-infection was seen in 6 patients. Four patients had GCGS isolates that clustered into clade C (nos. 41, 70, 82, 85), and the isolates were all associated with severe disease features (Technical Appendix 1 Table 2). Two of the 4 patients died.

Distribution of Virulence Factors

All 122 isolates carried virulence factors gapC, hylB, lmb, sagA, scpA, scpB, ska, skc, skg, and slo; however, virulence factors cba, cfb, cylE, fbsA, fnbA, and pavA were universally absent. Other factors were variably present (Table 3). Factors cbp, fbp, speG, sicG, gfbA, and bca clustered clonally into the phylogeny (Figure 1). All clade A and B isolates contained only speG, with the exception of 1 clade B isolate that also contained cbp, sicG, and gfbA. Clade C consisted of isolates with cbp, sicG, and gfbA; clade D isolates had cbp, fbp, and sicG; and clade E isolates had fbp, speG, and sicG. The virulence factor fbp was present in clades D and E and in 1 nonclade isolate (no. 28). Virulence factor bca was found variably in 5 nonclade isolates (nos. 49, 75, 74, 33, and 11) and in the reference isolate, AC-2713, which also contained genes speG and sicG. No association was discovered between the presence of these virulence factors and disease severity.

Clinical Outcomes within the Phylogeny

Severe disease features were present in a similar proportion of patients with GCGS disease caused by clade A–E isolates (63%, 40/64 patients) and heterogeneous nonclade isolates (68%, 17/25 patients). There was an observed trend toward increased mortality in patients with isolates from clades A–E (14 deaths) compared with patients with nonclade isolates (4 deaths), although the difference was not statistically significant (p = 0.7698). The number of deaths resulting from GCGS bacteremia caused by the most common clades, A–C (13/55 [24%]), was not significantly different than the number caused by other clades (5/34 [15%]; p = 0.4179). The death rate was also higher among patients with ST15, ST20, and ST17 (26% [14/53 patients]) than among patients with other STs (11% [4/36 patients]), but the difference was not significant (p = 0.1075).

Discussion

Our findings from this large study of the genomic epidemiology and molecular determinants of invasive GCGS bacteremia in association with the clinical features and outcomes of disease contribute to an evolving understanding of the changing epidemiology of β-hemolytic streptococcal infections. Similar to the findings of others (10), our findings showed that invasive infection is more common among older persons with underlying medical conditions. Although host factors probably contribute to changing epidemiology, enhanced GCGS virulence should be considered a contributor to the rising incidence GCGS bacteremia. We observed rates of severe disease (70%), ICU admission (26%), and toxic shock syndrome (17%) that were higher than those from previous reports, suggesting increased GCGS virulence (8). Death occurred among 17 (20%) of the 84 patients with invasive GCGS bacteremia, a finding consistent with those in other reports (710).

As expected, skin and soft tissue infections served as the main portal of entry in more than half the cases of invasive GCGS bacteremia; however, primary bacteremia without alternate sources of infection was seen in a higher proportion (37%) of cases than seen in other reports (3,5,14). Infections without a source of bacteria entry could represent more effective bacterial penetration of skin and mucosal barriers and evasion of the host immune response due to enhanced pathogenic mechanisms.

Organisms in clades B–E were entirely Lancefield group G and had higher rates of invasive infections, possibly suggesting acquired genetic determinants are contributing to increased virulence and evolutionary selection of these clades. However, in this study, no single genetic determinant could account for an organism’s ability to cause invasive infection. Although respiratory tract isolates in our study served as noninvasive controls, they were collected from persons with symptomatic pharyngitis, in whom host defenses might prevent severe infection and invasion into the blood stream. Host defenses may have obscured recognition of a shared invasion factor that could not be detected in our comparisons.

The virulence factor profiles we described were similar to those previously reported (11,18,22,23,35). However, sicG was present in a substantially higher proportion of isolates in our study (38.5%) than in another study (9.0%) (18), and it was primarily within clades C–E. The gene for bca, which has only rarely been described in SDSE, was present in a minority of our isolates (9.0%). The superantigen speG gene was found to cluster in Lancefield groups C and G, belonging to clades A and B, respectively, and was present in a proportion of isolates similar to that described in other reports (18,22). The reference isolate, AC-2713, also possessed all 3 of these virulence factors. All other superantigens found in GAS were absent from the isolates in our study.

The toxin gene sagA was present in all invasive and noninvasive isolates in our study. Although this toxin has previously been implicated in necrotizing skin and soft tissue infections (20), we did not confirm these findings in our study. No cases of necrotizing fasciitis were present in the study cohort; however, skin and soft tissue infections were common and severe, requiring surgical intervention in 17 (19%) of the 89 patients with bacteremia.

A specific cluster within clade C organisms was associated with polymicrobial bacteremia with S. aureus. All 4 patients co-infected with S. aureus and clade C GCGS organisms had severe infections: 2 patients, 1 of whom died, required renal replacement therapy; 1 was an intravenous drug user with endocarditis; and 1 was a 60-year-old man with diabetes who sought medical care for STSS from an unknown source and subsequently died. All isolates had cbp, sicG, and gfbA virulence factors. Three of the 4 patients had risk factors for endovascular infection; however, the clustering of these organisms may suggest a synergistic effect of co-infection and invasion with S. aureus.

Overall, the rising incidence and severity of invasive GCGS infections are probably associated with several evolving bacterial virulence factors. These factors probably take advantage of aging hosts with complex chronic diseases, susceptibilities, and co-existing conditions. Although our findings did not show a single virulence factor to account for emerging virulence, clonal clustering of factors within clades causing invasive infection suggests a survival and invasion advantage over clades without similar virulence clusters. Antimicrobial pressure may lead to accelerated transfer of genetic material, leading to acquisition of virulence factors. Furthermore, it is possible that newly acquired or novel virulence factors not previously described in other β-hemolytic streptococci are present.

In conclusion, the frequency of invasive GCGS infections is surpassing that of GAS infections in patients in Manitoba, Canada, and these infections are associated with severe disease and death. Related strains that cluster clonally are more likely than others to cause invasive disease. The clonal distribution of virulence factors, in combination with host factors, is probably contributing to the emergence of invasive GCGS.

Dr. Lother is an Infectious Disease fellow at the University of British Columbia. His primary interests are in streptococcal septic shock and endocarditis, particularly with regard to pathogenesis, virulence, epidemiology, and treatments.

Top

Acknowledgments

We acknowledge the staff at St-Boniface Hospital Microbiology Laboratory who collected control respiratory isolates and assisted with the culturing, identification, and shipment of organisms to the National Microbiology Laboratory (NML). We also acknowledge the hard work and collaboration of the staff from the Streptococcus and STI Unit at the NML. We express our gratitude to the staff of the NML Science Technology Cores and Services Division for the use of their infrastructure, analytical pipelines, technical support and guidance and to the NML Genomics Core Facility for their next-generation sequencing and analytical expertise. Without their interest and dedication to this project, this work would not have been possible.

Y.K. conceived and supervised this project. S.A.L. wrote the proposal for the study; obtained ethics approval for the research; performed retrospective chart reviews and analysis of clinical data; obtained, cultured, and identified the clinical isolates; and was the primary author of the manuscript. P.L.-W. oversaw the laboratory operations at St-Boniface hospital and provided the isolates. I.M. is section head of the Streptococcus and STI Unit at NML where Lancefield testing and whole-genome sequencing of isolates was performed. W.D. performed bioinformatic analyses. M.M. oversaw the laboratory operations at NML. B.D. performed statistical analyses. S.A.L. prepared the manuscript with significant contribution from W.D.

This work was supported by funding from the Public Health Agency of Canada.

Top

References

  1. Schwartz  IS, Keynan  Y, Gilmour  MW, Dufault  B, Lagacé-Wiens  P. Changing trends in β-hemolytic streptococcal bacteremia in Manitoba, Canada: 2007-2012. Int J Infect Dis. 2014;28:2113. DOIPubMed
  2. Nielsen  HU, Kolmos  HJ, Frimodt-Møller  N. Beta-hemolytic streptococcal bacteremia: a review of 241 cases. Scand J Infect Dis. 2002;34:4836. DOIPubMed
  3. Sylvetsky  N, Raveh  D, Schlesinger  Y, Rudensky  B, Yinnon  AM. Bacteremia due to beta-hemolytic Streptococcus group G: increasing incidence and clinical characteristics of patients. Am J Med. 2002;112:6226. DOIPubMed
  4. Lambertsen  LM, Ingels  H, Schønheyder  HC, Hoffmann  S; Danish Streptococcal Surveillance Collaboration Group 2011. Nationwide laboratory-based surveillance of invasive beta-haemolytic streptococci in Denmark from 2005 to 2011. Clin Microbiol Infect. 2014;20:O21623. DOIPubMed
  5. Rantala  S, Vuopio-Varkila  J, Vuento  R, Huhtala  H, Syrjänen  J. Clinical presentations and epidemiology of beta-haemolytic streptococcal bacteraemia: a population-based study. Clin Microbiol Infect. 2009;15:2868. DOIPubMed
  6. Harris  P, Siew  D-A, Proud  M, Buettner  P, Norton  R. Bacteraemia caused by beta-haemolytic streptococci in North Queensland: changing trends over a 14-year period. Clin Microbiol Infect. 2011;17:121622. DOIPubMed
  7. Ekelund  K, Skinhøj  P, Madsen  J, Konradsen  HB. Invasive group A, B, C and G streptococcal infections in Denmark 1999-2002: epidemiological and clinical aspects. Clin Microbiol Infect. 2005;11:56976. DOIPubMed
  8. Rantala  S, Vuopio-Varkila  J, Vuento  R, Huhtala  H, Syrjänen  J. Predictors of mortality in beta-hemolytic streptococcal bacteremia: a population-based study. J Infect. 2009;58:26672. DOIPubMed
  9. Bradley  SF, Gordon  JJ, Baumgartner  DD, Marasco  WA, Kauffman  CA. Group C streptococcal bacteremia: analysis of 88 cases. Rev Infect Dis. 1991;13:27080. DOIPubMed
  10. Broyles  LN, Van Beneden  C, Beall  B, Facklam  R, Shewmaker  PL, Malpiedi  P, et al. Population-based study of invasive disease due to beta-hemolytic streptococci of groups other than A and B. Clin Infect Dis. 2009;48:70612. DOIPubMed
  11. Shimomura  Y, Okumura  K, Murayama  SY, Yagi  J, Ubukata  K, Kirikae  T, et al. Complete genome sequencing and analysis of a Lancefield group G Streptococcus dysgalactiae subsp. equisimilis strain causing streptococcal toxic shock syndrome (STSS). BMC Genomics. 2011;12:17. DOIPubMed
  12. Bucher  A, Gaustad  P. Septicemia and endocarditis caused by group G streptococci in a Norwegian hospital. Eur J Clin Microbiol Infect Dis. 1990;9:2516. DOIPubMed
  13. Kristensen  B, Schønheyder  HC. A 13-year survey of bacteraemia due to beta-haemolytic streptococci in a Danish county. J Med Microbiol. 1995;43:637. DOIPubMed
  14. Schugk  J, Harjola  VP, Sivonen  A, Vuopio-Varkila  J, Valtonen  M. A clinical study of beta-haemolytic groups A, B, C and G streptococcal bacteremia in adults over an 8-year period. Scand J Infect Dis. 1997;29:2338. DOIPubMed
  15. McDonald  M, Towers  RJ, Andrews  RM, Carapetis  JR, Currie  BJ. Epidemiology of Streptococcus dysgalactiae subsp. equisimilis in tropical communities, Northern Australia. Emerg Infect Dis. 2007;13:1694700. DOIPubMed
  16. Bisno  AL, Collins  CM, Turner  JC. M proteins of group C streptococci isolated from patients with acute pharyngitis. J Clin Microbiol. 1996;34:25115.PubMed
  17. Leitner  E, Zollner-Schwetz  I, Zarfel  G, Masoud-Landgraf  L, Gehrer  M, Wagner-Eibel  U, et al. Prevalence of emm types and antimicrobial susceptibility of Streptococcus dysgalactiae subsp. equisimilis in Austria. Int J Med Microbiol. 2015;305:91824. DOIPubMed
  18. Davies  MR, McMillan  DJ, Beiko  RG, Barroso  V, Geffers  R, Sriprakash  KS, et al. Virulence profiling of Streptococcus dysgalactiae subspecies equisimilis isolated from infected humans reveals 2 distinct genetic lineages that do not segregate with their phenotypes or propensity to cause diseases. Clin Infect Dis. 2007;44:144254. DOIPubMed
  19. Nakagawa  I, Amano  A, Mizushima  N, Yamamoto  A, Yamaguchi  H, Kamimoto  T, et al. Autophagy defends cells against invading group A Streptococcus. Science. 2004;306:103740. DOIPubMed
  20. Humar  D, Datta  V, Bast  DJ, Beall  B, De Azavedo  JCS, Nizet  V. Streptolysin S and necrotising infections produced by group G streptococcus. Lancet. 2002;359:1249. DOIPubMed
  21. Commons  RJ, Smeesters  PR, Proft  T, Fraser  JD, Robins-Browne  R, Curtis  N. Streptococcal superantigens: categorization and clinical associations. Trends Mol Med. 2014;20:4862. DOIPubMed
  22. Lo  HH, Cheng  WS. Distribution of virulence factors and association with emm polymorphism or isolation site among beta-hemolytic group G Streptococcus dysgalactiae subspecies equisimilis. APMIS. 2015;123:4552. DOIPubMed
  23. Hashikawa  S, Iinuma  Y, Furushita  M, Ohkura  T, Nada  T, Torii  K, et al. Characterization of group C and G streptococcal strains that cause streptococcal toxic shock syndrome. J Clin Microbiol. 2004;42:18692. DOIPubMed
  24. Pinho  MD, Melo-Cristino  J, Ramirez  M. Clonal relationships between invasive and noninvasive Lancefield group C and G streptococci and emm-specific differences in invasiveness. J Clin Microbiol. 2006;44:8416. DOIPubMed
  25. Breiman  RF, Davis  JP, Facklam  RR, Gray  BM, Hoge  CW, Kaplan  EL, et al.; The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA. 1993;269:3901. DOIPubMed
  26. Kellett  J, Deane  B. The Simple Clinical Score predicts mortality for 30 days after admission to an acute medical unit. QJM. 2006;99:77181. DOIPubMed
  27. Olsson  T, Terent  A, Lind  L. Rapid Emergency Medicine score: a new prognostic tool for in-hospital mortality in nonsurgical emergency department patients. J Intern Med. 2004;255:57987. DOIPubMed
  28. Ghanem-Zoubi  NO, Vardi  M, Laor  A, Weber  G, Bitterman  H. Assessment of disease-severity scoring systems for patients with sepsis in general internal medicine departments. Crit Care. 2011;15:R95. DOIPubMed
  29. Magoč  T, Salzberg  SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 2011;27:295763. DOIPubMed
  30. Bankevich  A, Nurk  S, Antipov  D, Gurevich  AA, Dvorkin  M, Kulikov  AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:45577. DOIPubMed
  31. Seemann  T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30:20689. DOIPubMed
  32. Li  H, Handsaker  B, Wysoker  A, Fennell  T, Ruan  J, Homer  N, et al.; 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25:20789. DOIPubMed
  33. Guindon  S, Dufayard  J-F, Lefort  V, Anisimova  M, Hordijk  W, Gascuel  O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol. 2010;59:30721. DOIPubMed
  34. Ragonnet-Cronin  M, Hodcroft  E, Hué  S, Fearnhill  E, Delpech  V, Brown  AJL, et al.; UK HIV Drug Resistance Database. Automated analysis of phylogenetic clusters. BMC Bioinformatics. 2013;14:317. DOIPubMed
  35. Wang  X, Zhang  X, Zong  Z. Genome sequence and virulence factors of a group G Streptococcus dysgalactiae subsp. equisimilis strain with a new element carrying erm(B). Sci Rep. 2016;6:20389. DOIPubMed
  36. Francisco  AP, Vaz  C, Monteiro  PT, Melo-Cristino  J, Ramirez  M, Carriço  JA. PHYLOViZ: phylogenetic inference and data visualization for sequence based typing methods. BMC Bioinformatics. 2012;13:87. DOIPubMed
  37. Altschul  SF, Madden  TL, Schäffer  AA, Zhang  J, Zhang  Z, Miller  W, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25:3389402. DOIPubMed

Top

Figures
Tables

Top

Follow Up

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to http://www.medscape.org/journal/eid. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers.

You must be a registered user on http://www.medscape.org. If you are not registered on http://www.medscape.org, please click on the “Register” link on the right hand side of the website.

Only one answer is correct for each question. Once you successfully answer all post-test questions, you will be able to view and/or print your certificate. For questions regarding this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@medscape.net. American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please go to https://www.ama-assn.org. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.

Article Title:
Clonal Clusters and Virulence Factors of Group C and G Streptococcus Causing Severe Infections, Manitoba, Canada, 2012–2014

CME Questions

1.   Your patient is a 67-year-old man with group C and G Streptococcus (GCGS) bacteremia from a skin infection. According to the retrospective study by Lother and colleagues, which of the following statements about clinical features of patients with GCGS bacteremia is most accurate?

A. Younger patients were more likely to have GCGS bacteremia

B. An estimated 10% of patients had necrotizing fasciitis or pharyngitis

C. Comorbid conditions were common, predominantly cardiovascular disease (47%) and diabetes mellitus (43%)

D. Approximately half of patients had bacteremia from skin and soft tissue infection, and only 7% had primary bacteremia

2.   According to the retrospective study by Lother and colleagues, which of the following statements about outcomes in patients with GCGS bacteremia is correct?

A. Disease burden was lower than previously reported, suggesting decreased virulence of recently emerging strains

B. Half of patients were admitted to an intensive care unit (ICU)

C. In-hospital all-cause mortality rate was 10%

D. Vasopressors were needed in 19% of patients, and ventilator support was needed in 17%

3.   According to the retrospective study by Lother and colleagues, which of the following statements about genetic determinants of GCGS bacteremia is correct?

A. Seven unrelated genetic lineages were more likely to cause invasive disease

B. Virulence factors cbp, fbp, speG, sicG, gfbA, and bca clustered clonally into the clades more likely to cause invasive disease

C. Invasive infection could be attributed to a single genetic determinant

D. A specific cluster within clade E organisms was associated with polymicrobial bacteremia with Staphylococcus aureus

Activity Evaluation

1. The activity supported the learning objectives.

Strongly Disagree

 

 

 

Strongly Agree

1

2

3

4

5

2. The material was organized clearly for learning to occur.

Strongly Disagree

 

 

 

Strongly Agree

1

2

3

4

5

3. The content learned from this activity will impact my practice.

Strongly Disagree

 

 

 

Strongly Agree

1

2

3

4

5

4. The activity was presented objectively and free of commercial bias.

Strongly Disagree

 

 

 

Strongly Agree

1

2

3

4

5

Top

Cite This Article

DOI: 10.3201/eid2307.161259

Related Links

Table of Contents – Volume 23, Number 7—July 2017

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Sylvain A. Lother, University of Manitoba, BMSB 507-745 Bannatyne Ave, Winnipeg, Manitoba R3E 0J9, Canada

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: June 15, 2017
Page updated: June 15, 2017
Page reviewed: June 15, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external